BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its wholly owned subsidiary, Sucampo Pharma Europe, Ltd. (SPE), filed a Marketing Authorization Application (MAA) in Switzerland for AMITIZA (lubiprostone) for the indication of Chronic Idiopathic Constipation in adults. The MAA was filed with Swissmedic by Sucampo Pharmaceuticals’ branch office in Basel, Switzerland.
